
The Melbourne, Australia–based biotech company Avexa is getting closer to developing its antiviral HIV drug apricitabine (ATC), reports the Web site of The Australian national newspaper. ATC is for the treatment of patients who have drug-resistant HIV.
Avexa announced this week the results of its latest phase trial for ATC, and CEO Julian Chick said the drug exceeded expectations. All 47 patients in the 21-day trial showed significant improvement after taking ATC.
All of the patients who received ATC recorded more than an 85% reduction in the level of HIV in the blood, and one patient had a decrease of 99.7%. The patients in the control group had only a minimal reduction in HIV levels.
"The benefit to HIV patients is that it gives them another opportunity to reduce the virus levels in the blood, therefore prolonging their lives," said Chick.
No side effects were reported, and researchers found no evidence of an ATC-resistant virus developing during the trial phase.
Avexa plans to market ATC by 2010 in the United States, Europe, Asia, and Australia. Alexa hopes to sell about $70 million of new shares to fund the drug's development. (The Advocate)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.